[针对分散型大B细胞淋巴瘤中枢神经系统复发的不同预防策略]
Shuang Qu1, Li-Sheng Liao1, Yan-Bin Zheng2
1Department of Hematology, Shengli Clinical Medical College of Fujian Medical University Fujian Provincial Hospital, Fuzhou 350001, Fujian Province, China.
Zhongguo shi yan xue ye xue za zhi
|October 31, 2024
概括
列纳利多米德表明,与高剂量甲状腺素 (HD-MTX) 相比,在扩散性大B细胞淋巴瘤 (DLBCL) 患者中用于中枢神经系统 (CNS) 预防,改善无进展生存率和整体生存率的趋势. 这两种策略都显示出相似的中枢神经系统无复发生存率,并且耐受性良好,没有与治疗相关的死亡.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床药理学 临床药理学
更多相关视频
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
7.9K
08:49Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype
Published on: March 18, 2020
11.0K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...